The ELEVATUM study is designed to investigate how faricimab impacts DME in Black Americans. By enrolling, you'll contribute ...

Age-related macular degeneration (ARMD) is the leading cause of severe vision loss in the developed world for people over 55 ...

Diabetic macular edema remains an important cause of vision loss among patients with diabetes mellitus. Improved control of blood pressure and blood sugar, as well as photocoagulation, are ...

HORIZON: An Extension Study to Evaluate the Safety and Tolerability of Ranibizumab in Subjects with Choroidal Neovascularization Secondary to AMD or Macular Edema Secondary to RVO; PIER ...

Doctors treat diabetic macular edema (DME) in two ways. First, they tackle what's causing it, like high blood sugar or high blood pressure. Just keeping your levels close to normal can stop eye ...

When you have diabetes, it’s important to watch out for other serious health problems that can come along with it. Eye disease is a common condition that happens with diabetes. Blood sugar ...

“Vabysmo has been shown to be an effective first-line treatment for diabetic macular edema, and for the first time, we now ...

The global diabetic macular edema market is on a steady growth trajectory, with an expected valuation of approximately USD 4,120.9 million in 2024. The market is poised to surpass USD 4,642.9 million ...

Congress of the Asia-Pacific Vitreo-Retina Society, November 22 - 24, 2024Ophthalmology Innovation Summit XIV, November 23, 2024MELBOURNE, ...

Injection 8 mg from an extension study of the Phase 3 PHOTON trial in patients with diabetic macular edema (DME). At three years, the longer-term data showed the vast majority of EYLEA HD patients ...

a selective tyrosine kinase inhibitor formulated in proprietary bioerodible Durasert E™, for patients with diabetic macular edema (DME). DURAVYU 2.7mg demonstrated an early, sustained, and clinically ...